Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03284957 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer(AMEERA-1) | terminated | Phase 1 / Phase 2 | 136 | SanofiINDUSTRY | 10 | Nov 24, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 |
| clinicaltrials |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 11 | Bolt Biotherapeutics, Inc.INDUSTRY | 2 | Nov 20, 2025 | clinicaltrials |
| NCT04024436 | A Study of TAS-120 in Patients With Metastatic Breast Cancer | terminated | Phase 2 | 64 | Taiho Oncology, Inc.INDUSTRY | 7 | Nov 13, 2025 | clinicaltrials |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | terminated | Phase 2 | 26 | Mayo ClinicOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer(ELEVATE TNBC) | terminated | Phase 2 | 92 | Gilead SciencesINDUSTRY | 6 | Nov 4, 2025 | clinicaltrials |
| NCT03901469 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer(TNBC) | terminated | Phase 2 | 115 | Zenith EpigeneticsINDUSTRY | 4 | Oct 7, 2025 | clinicaltrials |
| NCT04136912 | 3-D Super Resolution Ultrasound Microvascular Imaging | terminated | Phase 2 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04108858 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03535506 | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery(WI223281) | terminated | Phase 2 | 17 | Georgetown UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04191382 | Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer(AMEERA-4) | terminated | Phase 2 | 105 | SanofiINDUSTRY | 9 | Sep 18, 2025 | clinicaltrials |
| NCT04249622 | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer | terminated | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT07166367 | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer | terminated | Phase 2 | 3 | National Cancer Centre, SingaporeOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | terminated | Phase 1 / Phase 2 | 10 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | terminated | Phase 2 | 17 | University of Alabama at BirminghamOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT02807597 | Real-time Intraoperative Breast Cancer Visualization for Margin Assessment | terminated | Phase 1 / Phase 2 | 9 | Samuel AchilefuOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | terminated | Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04227327 | Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)(HERMIONE-7) | terminated | Phase 2 | 31 | University of Milano BicoccaOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT03248492 | A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) | terminated | Phase 2 | 253 | Daiichi SankyoINDUSTRY | 9 | Jun 26, 2025 | clinicaltrials |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05243641 | Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | terminated | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer(neoBREASTIM) | terminated | Phase 1 / Phase 2 | 2 | Institut CurieOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04789096 | Tucatinib Together With Pembrolizumab and Trastuzumab(TUGETHER) | terminated | Phase 2 | 31 | Breast Cancer Trials, Australia and New ZealandOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04251169 | Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression(TATEN) | terminated | Phase 2 | 20 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer(PERSEVERE) | terminated | Phase 2 | 52 | Bryan Schneider, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | terminated | Phase 2 | 44 | University of UtahOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT00195091 | Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer | terminated | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04965688 | Biology Guided Therapy for Breast Cancer for ER Positive(SPOCK) | terminated | Phase 2 | 2 | Inova Health Care ServicesOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05336721 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | terminated | Phase 2 | 9 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Valerio TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | terminated | Phase 2 | 30 | G1 Therapeutics, Inc.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04440982 | Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients | terminated | Phase 2 | 98 | Lumicell, Inc.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04256941 | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT05176080 | Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors(CONTRAST) | terminated | Phase 1 / Phase 2 | 18 | BioInvent International ABINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT04675827 | De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade(Decrescendo) | terminated | Phase 2 | 139 | Jules Bordet InstituteOTHER | 6 | Dec 4, 2024 | clinicaltrials |
| NCT02317783 | Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment | terminated | Phase 2 | 15 | University of UtahOTHER | 1 | Nov 20, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2025source: clinicaltrials